Introduction {#tca13410-sec-0003}
============

Gastrointestinal tract (GIT) metastasis from lung carcinoma signifies a late stage disease resulting from hematogenous tumor spread. This possibility should be given serious consideration in patients with a previous history of initial lung carcinoma.[1](#tca13410-bib-0001){ref-type="ref"}, [2](#tca13410-bib-0002){ref-type="ref"}, [3](#tca13410-bib-0003){ref-type="ref"}

Here, we report a case wherein the medical background demonstrated that the patient encountered intensifying dysphagia and epigastralgia as the initial characteristic of gastric metastasis from primary lung squamous cell carcinoma (SCC) after curative surgery.

Case report {#tca13410-sec-0004}
===========

A 64‐year‐old male was admitted to our department complaining of epigastric pain and progressive dysphagia for more than one month. He had a smoking history of one and a half packs of cigarettes per day for 17 years. One year prior to the current presentation, the patient had been diagnosed with primary lung SCC of the right lower lobe (Fig. [1](#tca13410-fig-0001){ref-type="fig"}a), and had undergone thoracoscopic lower lobectomy. This was staged as pT2aN0M0, stage IB according to the eighth edition of the UICC classification. He then proceeded with adjuvant chemotherapy consisting of four cycles of uracil and tegafur.

![Computed tomography (CT) scan. (**a**) Chest scans indicated the presence of a right lower lobe nodule which measured 3.2 × 2.3 cm. (**b**) Abdominal scans showed a gastric fundal mass located in the gastric cardia which measured 5.2 × 5.0 cm.](TCA-11-1708-g001){#tca13410-fig-0001}

Computed tomography (CT) scan showed a gastric fundal mass located in the gastric cardia which measured 5 cm (Fig. [1](#tca13410-fig-0001){ref-type="fig"}b). Esophagogastroduodenoscopy (EGD) showed a 5 cm subepithelial and ulcerated mass located in the gastric cardia (Fig. [1](#tca13410-fig-0001){ref-type="fig"}c). Because the gastric biopsies had identified SCC, this tumor was suspected to be gastric metastasis from a primary lung SCC. CT scan just prior to surgery revealed remarkable growth of the tumor without any additional organ metastasis. The patient subsequently underwent proximal gastrectomy with resection of the diaphragmatic crus which was reconstructed by esophagogastrostomy one month after the diagnosis.

The gross appearance of the gastric lesion showed a hard mass with ulceration of 7.0 × 7.0 cm, which directly invaded the esophagus and diaphragm (Fig. [2](#tca13410-fig-0002){ref-type="fig"}). The postoperative histopathological features of the tumor revealed keratinizing SCC with massive submucosal infiltration and major vascular invasion (Fig. [3](#tca13410-fig-0003){ref-type="fig"}). A total of 17 lymph nodes were evaluated, and none showed any signs of malignancy. The histopathological report concluded that the tumor was a metastasis from primary lung SCC.

![Esophagogastroduodenoscopy showed a 5 cm subepithelial and ulcerated mass located in the gastric cardia.](TCA-11-1708-g002){#tca13410-fig-0002}

![Histopathological views. (**a**) Gastric specimens showing clear boundaries between the cancer tissue and normal gastric gland (hematoxylin and eosin staining × 40). (**b**) Morphology of the squamous cell carcinoma indicated by the arrowhead was similar to that of the primary tumor in the lung (hematoxylin and eosin staining × 200). (**c**) The squamous cell carcinoma indicated by the arrow is seen infiltrating into the blood vessels (hematoxylin and eosin staining × 200).](TCA-11-1708-g003){#tca13410-fig-0003}

He was discharged without any complications 14 days after the operation. Two months after surgery, a follow‐up CT scan showed that there was local recurrence with multiple lymph node metastases. He then received four courses of docetaxel and nedaplatin therapy (60 mg/m^2^ docetaxel and 100 mg/m^2^ nedaplatin on day one, every four weeks), but this treatment failed as a result of tumor progression. The patient subsequently received two courses of nivolumab therapy (3 mg/kg bodyweight on day one, every two weeks). At this time, CT scan indicated tumor progression and appearance of new liver metastasis. The patient\'s chemotherapy regime was then changed to atezolizumab therapy (1200 mg/kg bodyweight on day one, every three weeks). However, his tumor was getting worse, and he passed away one year after gastrectomy as a result of gastrointestinal bleeding.

Discussion {#tca13410-sec-0005}
==========

GIT metastasis from primary lung carcinoma is one of the rarest phenomena,[1](#tca13410-bib-0001){ref-type="ref"}, [3](#tca13410-bib-0003){ref-type="ref"}, [4](#tca13410-bib-0004){ref-type="ref"}, [5](#tca13410-bib-0005){ref-type="ref"}, [6](#tca13410-bib-0006){ref-type="ref"}, [7](#tca13410-bib-0007){ref-type="ref"}, [8](#tca13410-bib-0008){ref-type="ref"}, [9](#tca13410-bib-0009){ref-type="ref"}, [10](#tca13410-bib-0010){ref-type="ref"}, [11](#tca13410-bib-0011){ref-type="ref"}, [12](#tca13410-bib-0012){ref-type="ref"} and its frequency has been reported to range from 0.19%--5.1%.[6](#tca13410-bib-0006){ref-type="ref"}, [13](#tca13410-bib-0013){ref-type="ref"}, [14](#tca13410-bib-0014){ref-type="ref"}, [15](#tca13410-bib-0015){ref-type="ref"}, [16](#tca13410-bib-0016){ref-type="ref"} However, the reported incidence of GIT metastasis from primary lung carcinoma at post‐mortem is relatively high, ranging from 4.7% to 14%.[17](#tca13410-bib-0017){ref-type="ref"}, [18](#tca13410-bib-0018){ref-type="ref"} SCC is regarded as the most common type of lung carcinoma with the highest reported incidence of gastric metastasis.[19](#tca13410-bib-0019){ref-type="ref"} As a result of superior advances in chemotherapy, supportive care of lung carcinoma patients and increasing life span, we may more frequently encounter this type of metastatic tumor in the foreseeable future.[6](#tca13410-bib-0006){ref-type="ref"} Therefore, gastrointestinal symptoms in a known case of lung SCC should raise suspicion of advanced metastatic disease.

We summarize cases of gastric metastasis from primary lung SCC, which have previously been reported in the English literature (Table [1](#tca13410-tbl-0001){ref-type="table"}). Among the five cases of metachronous metastases, only one had a single metastasis in the stomach. This metastatic tumor was generally found above the body of the stomach except in one case. EGD showed that most cases of metastasis present as submucosal tumors with mucosal folds up and modest ulcerations towards the top, often referred to as volcano‐like ulcers. In general, tumors with these findings are regarded as hematogenous or lymphatic metastatic lesions, but this was not clarified in the previous reports. We considered our case to be that of a hematogenous metastasis as severe vascular, not lymphatic invasion was histologically detected around the tumor. However, the possibility of retrograde lymphatic spread from micrometastasis in the paraesophageal lymph nodes or in the pulmonary ligament to submucosal lymphatic vessels of the stomach must be a consideration.

###### 

Reported cases of gastric metastasis from primary lung squamous cell carcinoma published in the English literature

  No.        Author/year                                                       Age/sex   Synchronous or metachronous   Time between diagnosis of lung carcinoma and gastric metastasis   Single or multiple organ   Gastric location   Clinical presentation      Endoscopic findings
  ---------- ----------------------------------------------------------------- --------- ----------------------------- ----------------------------------------------------------------- -------------------------- ------------------ -------------------------- ---------------------
  1          Fletcher *et al*./ 1980[3](#tca13410-bib-0003){ref-type="ref"}    70/M      Synchronous                   ‐                                                                 Single                     Body               Perforation                Not performed
  2          Kim *et al*./ 1993[1](#tca13410-bib-0001){ref-type="ref"}         68/M      Synchronous                   ‐                                                                 Multiple                   Body               None                       SMT with ulcer
  3          Tamura *et al*. 2003[8](#tca13410-bib-0008){ref-type="ref"}       67/M      Metachronous                  12 months                                                         Single                     Cardia             Hematemesis                SMT with ulcer
  4          Alpar *et al*. 2006[7](#tca13410-bib-0007){ref-type="ref"}        66/M      Metachronous                  4 months                                                          Multiple                   unknown            Vomiting                   unknown
  5          Yang *et al*. 2006[6](#tca13410-bib-0006){ref-type="ref"}         65/M      Synchronous                   ‐                                                                 Multiple                   unknown            Melena                     unknown
  6          Yang *et al*. 2006[6](#tca13410-bib-0006){ref-type="ref"}         71/M      Synchronous                   ‐                                                                 Single                     unknown            Melena                     unknown
  7          Wu *et al*. 2007[5](#tca13410-bib-0005){ref-type="ref"}           73/M      Metachronous                  108 months                                                        unknwon                    Cardia             Melena                     unknown
  8          Ozdilekcan *et al*. 2010[9](#tca13410-bib-0009){ref-type="ref"}   46/M      Synchronous                   ‐                                                                 Single                     Body               Dysphagia, Epigastralgia   Ulcer
  9          Hu *et al*. 2013[2](#tca13410-bib-0002){ref-type="ref"}           54/M      Metachronous                  5 months                                                          Multiple                   Body               Dysphagia                  SMT with ulcer
  10         Kim *et al*. 2013[13](#tca13410-bib-0013){ref-type="ref"}         71/M      Synchronous                   ‐                                                                 Multiple                   Body               None                       Ulcer
  11         Miyazaki *et al*. 2015[10](#tca13410-bib-0010){ref-type="ref"}    54/M      Synchronous                   ‐                                                                 Multiple                   Antrum             Epigastralgia, anemia      Ulcer
  12         Bhardwaj *et al*. 2017[20](#tca13410-bib-0020){ref-type="ref"}    39/F      Synchronous                   ‐                                                                 Multiple                   Fundus             Dizziness, melena          SMT with ulcer
  13         Azar *et al*. 2017[12](#tca13410-bib-0012){ref-type="ref"}        90/M      Metachronous                  5 months                                                          Multiple                   Body               Melena                     SMT with ulcer
  14         Li *et al*. 2018[11](#tca13410-bib-0011){ref-type="ref"}          68/M      Synchronous                   ‐                                                                 Multiple                   Body               None                       SMT with ulcer
  15         He *et al*. 2019[19](#tca13410-bib-0019){ref-type="ref"}          61/M      Synchronous                   ‐                                                                 Single                     Cardia             Dysphagia                  SMT with ulcer
  Our case   Nemoto *et al*. 2019                                              64/M      Metachronous                  12 months                                                         Single                     Cardia             Epigastralgia              SMT with ulcer

F, female; M, male; SMT, submucosal tumor.

The prognosis of GIT metastases is very poor, with an average survival time of 96.5 days following initial diagnosis.[14](#tca13410-bib-0014){ref-type="ref"} In our case, the prognosis was better than those previously reported. Recent advances in chemotherapy and immunotherapy may also have contributed to a better prognosis in our case.

In conclusion, operative management may offer accessibility of risk‐free palliative remedy and provide extended survival with an enhanced quality of life. Nevertheless, substantial upgrades within the comprehending and restorative approaches for metastatic disease are required to boost the clinical consequences.

Disclosure {#tca13410-sec-0006}
==========

The authors declare there are no conflicts of interest.
